Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules (AceDoPC)

Civil Hospices of Lyon

Status: Completed

Conditions: Healthy Subject

Treatments: Drug: 13-C labeled PC-DHA; Drug: 13-C labeled AceDoPC-DHA; Drug: 13-C labeled TG-DHA

Study type: Interventional

Funder types: Other

Identifiers

NCT02168738

2012.778

Details and patient eligibility

About

The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules.

The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.

Enrollment: 4 patients

Sex: Male

Ages: 60 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male
• Aged of 60 to 70 years
• Body Mass Index of 20 to 30 kg/m2
• Glycaemic and lipid parameters normal

Exclusion criteria

• Smokers more than ten cigarettes/day
• Medical history of personal or family dyslipidemia
• Medication that could interfere with lipid metabolism

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

4 participants in 3 patient groups

13-C labeled PC-DHA

Active Comparator group

Treatment:

Drug: 13-C labeled TG-DHA

Drug: 13-C labeled AceDoPC-DHA

Drug: 13-C labeled PC-DHA

13-C labeled TG-DHA

Active Comparator group

Treatment:

Drug: 13-C labeled TG-DHA

Drug: 13-C labeled AceDoPC-DHA

Drug: 13-C labeled PC-DHA

13-C labeled AceDoPC-DHA

Experimental group

Treatment:

Drug: 13-C labeled TG-DHA

Drug: 13-C labeled AceDoPC-DHA

Drug: 13-C labeled PC-DHA